Rifampicin + Isoniazid + Pyrazinamide + Ethambutol (Ifamso-PE) is a high-potency, 4-drug fixed-dose combination (FDC) specifically designed for the intensive phase of Tuberculosis (TB) treatment. This synergistic formulation combines the most effective first-line antituberculosis agents into a single tablet to simplify therapy, improve patient compliance, and reduce the overall pill burden.
Each active ingredient plays a critical role in eradicating the Mycobacterium tuberculosis bacteria:
-
Rifampicin: A powerful bactericidal agent that kills actively dividing bacteria.
-
Isoniazid: A primary antituberculosis drug that targets the bacterial cell wall.
-
Pyrazinamide: A sterilizing agent that kills semi-dormant bacteria hiding within cells.
-
Ethambutol: A bacteriostatic agent that helps prevent the development of drug-resistant strains.
Ifamso-PE is indicated for the initial treatment of both pulmonary and extrapulmonary tuberculosis in accordance with the National Tuberculosis Program (NTP) guidelines. The film-coated tablets are formulated for consistent absorption and optimal therapeutic efficacy.
Key Benefits:
-
Comprehensive 4-in-1 Therapy: Covers all necessary first-line medications for the intensive phase of TB treatment.
-
Enhanced Compliance: Fewer pills to take daily reduces the risk of missed doses and treatment failure.
-
Prevents Drug Resistance: Fixed-dose combinations ensure that all four drugs are taken in the correct ratio, minimizing the emergence of multi-drug resistant TB (MDR-TB).
-
Targeted Bactericidal Action: Effectively kills bacteria in various stages of growth for faster recovery.
-
Value Box (84s): Convenient bulk packaging to support a consistent treatment course.





